Ianalumab plus Eltrombopag in Immune Thrombocytopenia

Abstract

Ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag. (Funded by Novartis; VAYHIT2 ClinicalTrials.gov number, NCT05653219.).

Affiliated Institutions

• Harvard University US
• Assistance Publique – Hôpitaux de Paris FR
• Institute of Hematology & Blood Diseases Hospital CN
• Azienda Sanitaria Universitaria Integrata di Trieste IT
• Østfold Hospital Trust
• Japanese Red Cross Nagoya Daiichi Hospital JP
• Southern Medical University CN
• Siriraj Hospital TH
• Chang Gung Memorial Hospital TW
• Istituti di Ricovero e Cura a Carattere Scientifico IT
• University Hospital Cologne DE
• University of Pennsylvania US
• University of Oslo
• Seoul St. Mary's Hospital KR
• Hôpitaux Universitaires Henri-Mondor FR
• All India Institute of Medical Sciences IN
• Nanfang Hospital CN
• Massachusetts General Hospital US
• Utrecht University NL
• Università Cattolica del Sacro Cuore IT
• Düsseldorf University Hospital DE
• Mahidol University TH
• Qilu Hospital of Shandong University CN
• Yamanashi Prefectural Central Hospital JP
• Novartis (Switzerland) CH
• AZ Delta BE
• Imperial College London GB
• Jena University Hospital DE
• Université Paris-Est Créteil FR
• University Medical Center Utrecht NL
• University of Trieste IT
• Catholic University of Korea KR
• Chang Gung University TW
• Sultanah Aminah Hospital MY
• University Hospital Brno CZ
• Chinese Academy of Medical Sciences & Peking Union Medical College CN

Related Publications